Epizyme is a biopharmaceutical company that is focused on rewriting treatment for people with cancer and other serious diseases through the discovery, development, and commercialization of epigenetic medicines. Co. has one approved product, TAZVERIK (tazemetostat), which was granted approval by the U.S. Food and Drug Administration (FDA) for epithelioid sarcoma (ES), and follicular lymphoma (FL). The FDA has granted approval of TAZVERIK (tazemetostat), an oral, selective small molecule inhibitor of the EZH2 histone methyltransferase for the treatment of adult and pediatric patients aged 16 years and older with metastatic or locally advanced ES not eligible for complete resection. The EPZM average annual return since 2013 is shown above.
The Average Annual Return on the EPZM average annual return since 2013 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether EPZM average annual return since 2013 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the EPZM average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free EPZM Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
